REVANESSE VERSA+ 1.0 ML

Additional Manufacturer Narrative

THE CLINICAL COMPLAINT HAS BEEN ADEQUATELY INVESTIGATED. THE LOT NUMBER HAS BEEN VERIFIED AND HAS BEEN CONFIRMED TO BE RELEASED BY THE COMPANY. IT HAS BEEN CONFIRMED THAT NO PREVIOUS CLINICAL COMPLAINTS HAVE BEEN FOUND FOR THE PARTICULAR LOT NUMBER IN QUESTION. THE BATCH RECORD, QC TEST REPORTS, AND TRAINING OF STAFF WERE ANALYSED AND IT HAS BEEN DETERMINED THAT PRODUCT IS WITHIN REQUIRED SPECIFICATIONS, AND MANUFACTURED ACCORDING TO APPROPRIATE PROCEDURES. THIS COMPLAINT IS CONSIDERED AS OFF LABEL USE AND THE CLINIC HAVE BEEN INFORMED BY PROLLENIUM MEDICAL TECHNOLOGIES THAT INJECTIONS INTO UNAPPROVED AREAS SUCH AS THE CHIN, LIPS, LOWER EYELID, TEAR TROUGHS AND MEDIAL CHEEKS ARE TO BE AVOIDED AS STATED IN THE REVANESSE® VERSATM+ DIRECTIONS FOR USE (DFU) AVAILABLE AT WWW.HTTP://REVANESSEUSADFU.COM/. PROLLENIUM MEDICAL TECHNOLOGIES' MEDICAL DIRECTOR'S RESPONSE TO THIS ADVERSE EVENT WAS PROVIDED TO THE CLINIC. THE RESPONSE FROM MEDICAL DIRECTOR IS AS FOLLOWS: "THE FOLLOWING IS A MEDICAL OPINION BASED ON THE INFORMATION DOCUMENTED IN THE COMPLAINT BELOW; ON (B)(6) 2021 THE PATIENT HAD 1.5 MLS OF VERSA HA INJECTED INTO HER MENTALIS REGION. SPECIFIC AREA AND DEPTH WAS NOT DOCUMENTED. BOTH THE PRE AND POST PHOTOS SHOW A VERY STRONG AND ACTIVE MENTALIST MUSCLE WITH SIGNIFICANT PEAU D'ORANGE DIMPLING. AT NO TIME DID THE PATIENT OR INJECTOR COMPLAIN ABOUT OR DESCRIBE AN ADVERSE EVENT. APPROXIMATELY 5 WEEKS LATER THE PATIENT COMPLAINED THAT THE CLINICAL EFFECT OF THE INJECTED FILLER WAS NOT AS APPARENT. THERE IS NO HISTORY OF THE PRODUCT BEING EXOGENOUSLY DISSOLVED OR MANIPULATED. THERE IS NO HISTORY OF ANY INFLAMMATORY REACTION IN THE AREA. NO VACCINE HISTORY WAS PROVIDED. IT IS WELL ESTABLISHED THAT UNLESS DISSOLVED BY HYALURONIDASE, HA DOES NOT "DISAPPEAR". ULTRASOUND STUDIES SHOW THAT IT INTEGRATES INTO TISSUE PLANES AND LAST FOR SEVERAL YEARS. WHAT DOES CHANGE IS THE CLINICAL APPEARANCE OF AN INJECTED AREA. THIS IS USUALLY CAUSED BY EXTERNAL FORCES SUCH AS SLEEPING ON THE AREA, MASSAGE OR COMPRESSION OF THE AREA OR COMPRESSION OF PRODUCT BETWEEN MUSCLES AND BONE. THE LATER IS VERY COMMONLY SEEN IN THE CHIN / MENTALIS AREA SO WHAT MOST INJECTORS DO IS BLOCK THE MENTALIS FUNCTION WITH NEUROMODULATORS AND PERFORM A TOUCH UP TO THE AREA IN 2-3 MONTHS. THE DEPTH AND QUANTITY OF HA DEPOSITION IN THIS AREA IS ALSO CRITICALLY IMPORTANT. THIS CASE DOES NOT REPRESENT AN ADVERSE EVENT. I HOPE THIS MEDICAL OPINION IS OF VALUE TO ALL PARTIES INVOLVED."

Description of Event or Problem

BASED ON THE INFORMATION PROVIDED FROM INJECTOR, PATIENT - FEMALE, (B)(6) Y.O., CAUCASIAN. NOT FIRST-TIME FILLER TREATMENT. ON (B)(6) 2021 - DATE OF TREATMENT WITH 1.5 SYRINGE OF REVANESSE VERSA+ 1.0 ML IN THE MENTALIST AREA OF THE PATIENT. PATIENT DID NOT HAVE ANY ADVERSE EVENTS. THREE WEEKS AFTER INITIAL TREATMENT, PATIENT WAS VERY MUCH SATISFIED. HOWEVER, ON (B)(6) 2021, REVANESSE VERSA+ FILLER IS COMPLETELY GONE FROM THE CHIN AS STATED BY PATIENT. PATIENT HAD SIMILAR REVANESSE VERSA FILLER TREATMENT IN APRIL 2019 IN LOWER ORBITAL AREA, HOWEVER, FILLERS HAVE RETAINED IN THAT AREA. THIS TIME FILLER DISAPPEARED IN A LITTLE MORE THAN A MONTH TIME. PATIENT RECEIVED COVID-19 VACCINE A MONTH BEFORE TREATMENT DATES. ACCORDING TO INJECTOR PATIENT DOES NOT HAVE ANY SIGNIFICANT MEDICAL HISTORY AS OF TREATMENT DATE. NKDA (NO KNOWN DRUG ALLERGIES).